Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient’s immune system fight the disease.
There is only one vaccine for tuberculosis, developed in 1921. It is unreliable in preventing the most common form of TB, and is not suitable in all patient groups. The vaccine works best against specific forms of TB and is usually given to infants in at-risk populations.
Tuberculosis is one of the top 10 causes of death worldwide. The World Health Organization (WHO) data show that 10 million people fell ill with TB and 1.6 million died from the disease in 2017. WHO estimates that there were 558,000 new cases with resistance to the most effective first-line antibiotic. Of those resistant to the drug, 82% were resistant to multiple antibiotics.
Funded by the Health Research Board (HRB) and the Royal City of Dublin Hospital Trust, the research is published in the European Journal of Pharmaceutics & Biopharmaceutics.
The work, led by Dr Gemma O’Connor and Prof Sally-Ann Cryan in RCSI, was carried out in collaboration with research teams in St James Hospital, Trinity College Dublin and Imperial College London. Prof Joseph Keane and Dr Mary O’Sullivan led the team at St James Hospital and Trinity College Dublin with Dr Brian Robertson and Dr Nitya Krishnan leading the team at Imperial College London.
Multidrug-resistant TB (MDR-TB) is seen as both a public health crisis and a health security threat. Ending the TB epidemic by 2030 is listed among the health targets of the United Nations Sustainable Development Goals.
The pathogen that causes tuberculosis spreads by people breathing infected droplets into their lungs, where the disease can remain dormant or spread further. The research makes use of a derivative of Vitamin A called all trans retinoic acid, atRA, which previous studies have shown is an effective treatment for tuberculosis.
“Many cases of TB are now becoming resistant to existing antibiotics. This new treatment could be used alongside antibiotics to treat drug-resistant TB and also possibly reduce the rate of antibiotic resistance resulting from conventional antibiotic treatments,” said Prof Cryan, Associate Professor of Pharmaceutics in RCSI School of Pharmacy and the study’s senior author.
Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler. These particles efficiently delivered the treatment and significantly reduced tuberculosis-causing bacteria and associated lung damage, which supports their potential for clinical testing.
“Unfortunately, tuberculosis remains a significant problem for world health. We urgently need innovative treatments like this one if we are to achieve the UN 2030 health targets,” said Prof Keane, Professor at Trinity College Dublin School of Medicine and Consultant Respiratory Physician in St James’s Hospital.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studieson May 11, 2020 at 2:26 am
Non-adherence to anti-tuberculosis (anti-TB) medication is a major risk factor for poor treatment outcomes. We therefore assessed the effectiveness of medication adherence enhancing interventions in ...
- Can a tuberculosis vaccine help combat COVID-19?on May 11, 2020 at 12:36 am
VPM1002 is the name of a new tuberculosis vaccine that could possibly help control the novel coronavirus. Several studies have been initiated and seem promising.
- COVID-19 could accelerate activation of dormant tuberculosis (TB)on May 10, 2020 at 7:32 pm
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and ...
- Covid-19, tuberculosis, meningitis — it's all business as usual for this nurse of 50 yearson May 8, 2020 at 5:45 pm
Voices of the Pandemic features people in the Seattle area who are on the front lines of the coronavirus outbreak.
- Could a 100-year-old vaccine for tuberculosis protect against coronavirus?on May 8, 2020 at 6:52 am
This week, the Bill and Melinda Gates Foundation announced it will donate A$10 million to help fund an Australian trial testing whether a very old vaccine, BCG, can be used against a new threat, COVID ...
- Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infectionon May 8, 2020 at 2:34 am
Inflammasome activation is a response to bacterial infection but can cause damage and spread infection. Here, the authors use live single-cell imaging to show two mechanisms by which M. tuberculosis ...
- Texas A&M researchers hope tuberculosis vaccine might prevent coronavirus deathson May 6, 2020 at 2:00 pm
Health care workers are being recruited for trials to test whether a decades-old TB vaccine might help people fight off the coronavirus. It's not a cure, but it could be a crucial treatment.
- Study Shows 6.3 Million People Could Develop Tuberculosis Because of Coronavirus Lockdownon May 6, 2020 at 6:45 am
A recent study warned that up to 6.3 million people could develop tuberculosis over the next five years because of the long-term implications of new coronavirus lockdowns. The 6.3 million worldwide ...
- Why coronavirus lockdown could see 6.3 million more people get tuberculosison May 6, 2020 at 6:24 am
Around 1.4 million more people could die of tuberculosis (TB) by 2025 due to the impact of the coronavirus pandemic on the fight against the infection, predicts new research.
- Tuberculosis cases, deaths will rise due to COVID-19 crisis, study warnson May 6, 2020 at 5:30 am
The analysis says coronavirus lockdown measures will likely lead to as many as 6.3 million new tuberculosis cases between now and 2025 because many patients will go undiagnosed and untreated.
via Bing News